BioCentury | Oct 5, 2015
Company News

Cardiome, Eddingpharm deal

...Cardiome’s Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to commercialize Aggrastat tirofiban in China. The...
...Aggrastat in China. Cardiome gained ex-U.S. rights to Aggrastat through its November 2013 acquisition of Correvio LLC...
BioCentury | Aug 17, 2015
Clinical News

Aggrastat tirofiban regulatory update

...percutaneous transluminal coronary angioplasty (PTCA). Cardiome gained rights to Aggrastat through its 2013 acquisition of Correvio LLC...
BioCentury | Sep 22, 2014
Company News

Cardiome, Eurolab deal

...Cardiome's Correvio International S.a.r.l. subsidiary granted Eurolab exclusive rights to commercialize IV Brinavess vernakalant in Argentina...
BioCentury | Jun 2, 2014
Company News

AOP Orphan, Cardiome deal

...are not disclosed. Cardiome gained ex-U.S. rights to Aggrastat through its November 2013 acquisition of Correvio LLC...
BioCentury | May 19, 2014
Company News

Proteros management update

...chemistry/biology, Supply/Service Hired: Michael Grau as CFO, formerly group CFO and chief compliance officer of Correvio LLC...
BioCentury | Feb 17, 2014
Company News

Cardiome, Phoenix Pharmahandel sales and marketing update

...Cardiome's Correvio GmbH subsidiary granted Phoenix Pharmahandel’s Tamro AB subsidiary rights to distribute IV Brinavess vernakalant...
BioCentury | Feb 3, 2014
Analyst Picks & Changes

Analyst picks & changes

...traction" in Europe where it is marketed as Brinavess, and that Cardiome's recent acquisition of Correvio LLC...
BioCentury | Nov 25, 2013
Company News

Cardiome, Correvio deal

...Cardiome acquired cardiovascular company Correvio in a cash and stock deal. Correvio shareholders received 19.9% of...
...equal to 10% of product sales plus 10% compounded annual interest by Dec. 1, 2019. Correvio...
...will accelerate the launch of its IV Brinavess vernakalant using financing from Aggrastat sales and Correvio's...
Items per page:
1 - 8 of 8
BioCentury | Oct 5, 2015
Company News

Cardiome, Eddingpharm deal

...Cardiome’s Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to commercialize Aggrastat tirofiban in China. The...
...Aggrastat in China. Cardiome gained ex-U.S. rights to Aggrastat through its November 2013 acquisition of Correvio LLC...
BioCentury | Aug 17, 2015
Clinical News

Aggrastat tirofiban regulatory update

...percutaneous transluminal coronary angioplasty (PTCA). Cardiome gained rights to Aggrastat through its 2013 acquisition of Correvio LLC...
BioCentury | Sep 22, 2014
Company News

Cardiome, Eurolab deal

...Cardiome's Correvio International S.a.r.l. subsidiary granted Eurolab exclusive rights to commercialize IV Brinavess vernakalant in Argentina...
BioCentury | Jun 2, 2014
Company News

AOP Orphan, Cardiome deal

...are not disclosed. Cardiome gained ex-U.S. rights to Aggrastat through its November 2013 acquisition of Correvio LLC...
BioCentury | May 19, 2014
Company News

Proteros management update

...chemistry/biology, Supply/Service Hired: Michael Grau as CFO, formerly group CFO and chief compliance officer of Correvio LLC...
BioCentury | Feb 17, 2014
Company News

Cardiome, Phoenix Pharmahandel sales and marketing update

...Cardiome's Correvio GmbH subsidiary granted Phoenix Pharmahandel’s Tamro AB subsidiary rights to distribute IV Brinavess vernakalant...
BioCentury | Feb 3, 2014
Analyst Picks & Changes

Analyst picks & changes

...traction" in Europe where it is marketed as Brinavess, and that Cardiome's recent acquisition of Correvio LLC...
BioCentury | Nov 25, 2013
Company News

Cardiome, Correvio deal

...Cardiome acquired cardiovascular company Correvio in a cash and stock deal. Correvio shareholders received 19.9% of...
...equal to 10% of product sales plus 10% compounded annual interest by Dec. 1, 2019. Correvio...
...will accelerate the launch of its IV Brinavess vernakalant using financing from Aggrastat sales and Correvio's...
Items per page:
1 - 8 of 8